EP2137143A1 — Pleuromutilin derivatives for the treatment of diseases mediated by microbes
Assigned to Nabriva Therapeutics AG · Expires 2009-12-30 · 16y expired
What this patent protects
A compound of formula (I) wherein n is 0 to 4; m is 0 or 1 with the proviso that the sulphur atom and R3 are in vicinal position (if m = 0 then R3 is in position 2', and if m = 1 then R3 is on position 1'); R is ethyl or vinyl; R1 is hydrogen or (C1-6)alkyl; R2 is hydrogen or - (…
USPTO Abstract
A compound of formula (I) wherein n is 0 to 4; m is 0 or 1 with the proviso that the sulphur atom and R3 are in vicinal position (if m = 0 then R3 is in position 2', and if m = 1 then R3 is on position 1'); R is ethyl or vinyl; R1 is hydrogen or (C1-6)alkyl; R2 is hydrogen or - (C3-6)cycloalkyl, or - unsubstituted (C1-6)alkyl, or - (C1-6)alkyl substituted by one or more of - hydroxy; preferably one or two, - methoxy, - halogen, - (C3-6)cycloalkyl, or R1 and R2 together with the nitrogen atom to which they are attached form a 5 to 7 membered heterocyclic ring containing at least 1 nitrogen atom or 1 nitrogen and 1 additional heteroatome e. g. selected from N or O, or R1 is hydroxy and R2 is formyl; R3 is OH, OR4, a halogen atom, or - with the proviso that R3 is bound to 2' R3 represents -O-(CH2)P-O- with p is 2 or 3; R4 is unsubstituted (C1-6)alkyl or (C3-6)cycloalkyl.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.